CLAIMS

1. Use of a pharmaceutically effective amount of dihydroberberine in the manufacture of a medicament for managing glucose tolerance in an individual, wherein the medicament is to be administered to an individual, and wherein the pharmaceutically effective amount of dihydroberberine comprises 25 mg to 800 mg of dihydroberberine.

2. The use of claim 1 wherein the administration of the medicament reduces fasting glucose levels.

3. The use of claim 1 wherein the dihydroberberine is to be administered as a complexed composition, and wherein the complexed composition further comprises at least one of complexed phytosomes or liposomes.

4. The use of claim 1 wherein the dihydroberberine is a microemulsion including dihydroberberine.

5. The use of claim 1 wherein the medicament is to be orally administered.

6. The use of claim 5 wherein the medicament is to be orally administered as a capsule or tablet.

7. The use of claim 1 wherein the medicament is to be administered at least once daily.

8. The use of claim 1 wherein the medicament further comprises a Cytochrome P450 inhibitor.

9. Use of a composition comprising 25 mg to 800 mg of dihydroberberine in the manufacture of a medicament for treating diabetes.

10. The use of claim 9 wherein the medicament is to be administered approximately concurrently with meals.

11. The use of claim 1 wherein the medicament is to be administered in combination with a medium chain fatty acid.